Cargando…

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy

BACKGROUND: Ovarian cancer shows considerable heterogeneity in its sensitivity to chemotherapy both clinically and in vitro. This study tested the hypothesis that the molecular basis of this difference lies within the known resistance mechanisms inherent to these patients' tumours. METHODS: The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glaysher, S, Gabriel, F G, Johnson, P, Polak, M, Knight, L A, Parker, K, Poole, M, Narayanan, A, Cree, I A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938260/ https://www.ncbi.nlm.nih.gov/pubmed/20700122 http://dx.doi.org/10.1038/sj.bjc.6605817

Ejemplares similares

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2014)

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines
por: Sawers, L, et al.
Publicado: (2014)

Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy
por: Wynne, P, et al.
Publicado: (2007)

Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy
por: Shehata, M, et al.
Publicado: (2009)

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer
por: Koti, M, et al.
Publicado: (2015)

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer
por: Smith, G, et al.
Publicado: (2012)

Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity
por: Jia, H, et al.
Publicado: (2010)

An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy
por: Qi, Lishuang, et al.
Publicado: (2016)

γ-Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate
por: Kim, S-E, et al.
Publicado: (2013)

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
por: Liu, W M, et al.
Publicado: (2010)

A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma
por: Yashiro, M, et al.
Publicado: (2013)

Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade
por: Loebinger, M R, et al.
Publicado: (2008)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
por: Wilbaux, M, et al.
Publicado: (2014)

Transport kinetics of four- and six-coordinate platinum compounds in the multicell layer tumour model
por: Modok, S, et al.
Publicado: (2007)

Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells
por: Ammerpohl, O, et al.
Publicado: (2007)

Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer
por: Tanaka, N, et al.
Publicado: (2011)

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
por: Iwasa, T, et al.
Publicado: (2010)

Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair
por: Ratner, Elena S, et al.
Publicado: (2016)

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer
por: Abdel-Fatah, T M A, et al.
Publicado: (2014)

Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents
por: He, G, et al.
Publicado: (2013)

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma
por: White, N M A, et al.
Publicado: (2009)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

Tyrphostins reduce chemotherapy-induced intestinal injury in mice: assessment by a biochemical assay
por: Zlotnik, Y, et al.
Publicado: (2005)

In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
por: Ashley, D M, et al.
Publicado: (2008)

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study
por: Köbel, M, et al.
Publicado: (2014)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21
por: He, G, et al.
Publicado: (2006)

Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis
por: Roos, Alison, et al.
Publicado: (2015)

Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis
por: Yokoyama, H, et al.
Publicado: (2006)

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer
por: Meng, F, et al.
Publicado: (2013)

Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer
por: White, N M A, et al.
Publicado: (2010)

Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy
por: de Graaff, Marieke A, et al.
Publicado: (2016)

Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies
por: McCoy, M J, et al.
Publicado: (2012)

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
por: Lorusso, D, et al.
Publicado: (2012)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition
por: Ding, X, et al.
Publicado: (2009)

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
por: Nakayama, N, et al.
Publicado: (2008)

Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
por: Azimi, A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gad3u2cl9k94t71e55b24uc7tf